Jason A. ZellAssistant Adjunct Professor, Medicine Assistant Adjunct Professor, Epidemiology |
|
|
Research Interests |
Cancer prevention, aerodigestive and gastrointestinal malignancies, genetic epidemiology | |
| URLs | Div. of Hematology/Oncology - Dept. of Medicine | |
| Dept. of Epidemiology - School of Medicine | ||
|
Academic Distinctions | Cum Laude, UCSB (1994); Northwest Osteopathic Medical Foundation-Scholarship Recipient (1999); NSU Family Medicine/Master of Public Health-Scholarship Receipient (1999-2001); Graduate with Honors, Nova Southeastern University (NSU)-COM (2001); Graduate with Highest Honors, NSU-Master of Public Health Program; Psi Sigma Alpha National Scholastic Osteopathic Honors Society (2001); UCI Department of Medicine, Internal Medicine Resident of the Year (2002-2003,PGY-2 Class), Delta Omega National Public Health Honor Society, Nova Southeastern University, Alpha XI Chapter (2005); 11th World Conference on Lung Cancer-Travel Award Recipient (Barcelona, Spain 2005); AACR Colorectal Cancer Conference-Scholar in Training Award (Dana Point, CA 2005); National Lung Cancer Partnership-Travel Award Recipient (Atlanta, GA 2005); 2007 Annual Conference Poster Session, NAACCR-First Place-Epidemiologic Studies (Detroit, MI 2007); 12th World Conference on Lung Cancer, IASLC-Young Investigator Award (Seoul, Korea 2007); Southwest Oncology (SWOG) Young Investigator Award(Seattle, WA 2008). | |
|
Research Abstract |
Dr. Zell’s research focus is cancer prevention of aerodigestive and gastrointestinal malignancies (e.g. lung, colon, pancreas), including prevention of secondary malignancies in patients with a history of established cancer. In particular, he is interested in cancer prevention through targeted manipulation of two key biologic pathways involved in tumorigenesis: polyamine synthesis and EGFR-signaling. Dr. Zell’s research involves analytic and genetic epidemiologic methods to identify high-risk populations for cancer development, or cancer recurrence. Subsequently, clinical trials are developed to test novel targeted approaches to cancer prevention among these high-risk groups. Currently he serves as principle investigator or co-investigator for several early phase secondary and tertiary cancer prevention clinical trials involving polyamine inhibition or EGFR inhibition. | |
| Publications |
Selected published journal manuscripts 1) Zell, JA*, Ou, S-HI, Ziogas, A, Anton-Culver, H. Epidemiology of bronchioloalveolar carcinoma: improvement in survival after release of the 1999 WHO classification of lung tumors. J Clin Oncol 2005 Nov 23(33):8396-8405. 2) Zell, JA*, Ou, S-HI, Ziogas, A, Anton-Culver, H. Long-term survival differences for bronchioloalveolar carcinoma patients with ipsilateral intrapulmonary metastasis at diagnosis. Ann Oncol 2006 Aug, 17(8):1255-1262. 3) Raz, DJ, Zell, JA, Karnezis, AN, Odisho A, Ou, S-HI, Anton-Culver, H, Jablons DM. Misclassification of bronchioloalveolar carcinoma with cytologic diagnosis of lung cancer. J Thor Oncol 2006 Nov, 1:943-948. 4) Ou, S-HI, Zell, JA, Ziogas, A, Anton-Culver, H. Epidemiology of nasopharyngeal carcinoma in the United States: improved survival of Chinese patients within the keratinizing squamous cell carcinoma histology. Ann Oncol 2007 Jan;18(1):29-35. Epub 2006 Oct 23. 5) Zell, JA*, Ignatenko, NA, Yerushalmi, H, Ziogas, A, Besselsen, DG, Gerner, EW, Anton-Culver, H. Risk and risk reduction involving arginine intake and meat consumption in colorectal tumorigenesis and survival. Int J Cancer 2007 Feb, 120(3):459-468. 6) Zell, JA*, Rhee, JM, Ziogas, A, Lipkin, SM, Anton-Culver, H. Race, socioeconomic status, treatment, and survival time among pancreatic cancer cases in California. Cancer Epi Biomarkers & Prevention 2007 March, 16(3):546-552. 7) Raz, DJ, Zell, JA, Ou, S-HI, Gandara, DR, Anton-Culver, H, Jablons DM. Natural history of stage I NSCLC: poor survival of untreated patients and implications for early detection. Chest, 2007 July, 132:193-199. 8) Ou, S-HI, Zell, JA, Ziogas, A, Anton-Culver, H. Prognostic factors for survival of stage I non-small cell lung cancer (NSCLC) patients: a population-based analysis of 19,702 stage I patients in the California Cancer Registry (CCR) from 1989 to 2003. Cancer 2007 Oct 1; 110(7):1532-41. 9) Zell, JA*, McEligot, A, Ziogas, A, Holcombe, RF, Anton-Culver, H. Differential effects of wine consumption on colorectal cancer outcomes based on family history of the disease. Nutrition & Cancer, 2007 Oct. Volume 59(1): 36-45. 10) Ou, S-HI, Zell, JA, Ziogas, A, Anton-Culver, H. Prognostic significance of the non-size based AJCC T2 descriptors: visceral pleura invasion (VPI), hilar atelectasis or obstructive pneumonitis in stage IB non-small-cell lung cancer (NSCLC) is dependent on tumor size. Chest, 2008 March, 133: 662-669; [Epub ahead of print Oct 9, 2007]; PMID: 17925418. 11) Zell, JA*, Ou, S-HI, Ziogas, A, Anton-Culver, H. Survival Improvements for Advanced Stage non-Bronchioloalveolar Carcinoma-type Non-Small-Cell Lung Cancer Cases with Ipsilateral Intrapulmonary Metastasis. Cancer, 2008 January, 112 (1): 136-143. 12) Zell, JA*, Ou, S-HI, Ziogas, A, Anton-Culver, H. Validation of the Proposed International Association for the Study of Lung Cancer Non-small Cell Lung Cancer Staging System Revisions for Advanced Bronchioloalveolar Carcinoma Using Data from the California Cancer Registry. J Thor Oncol, 2007 Dec, 2(12): 1078-1085. 13) Zell, JA*, Cinar, P, Mobasher, M, Ziogas, A, Meyskens, FL, Anton-Culver, H. The effects of race, socioeconomic status, and treatment on survival for invasive cutaneous melanoma cases. J Clin Oncol, 2008 Jan, 26(1): 66-75. 14) Ou, S-HI, and Zell, JA* Validation study of the proposed IASLC staging revisions of the T4 and M Non-Small Cell Lung Cancer descriptors using data from 23,583 patients in the California Cancer Registry. J Thor Oncol, 2008, March, Vol 3 (3): 216-227. 15) Ou, S-HI, Zell, JA, Ziogas, A, Anton-Culver, H. Low socioeconomic status is a poor prognostic factor for survival in stage I non-small-cell lung cancer and is independent of surgical treatment, race, and marital status. Cancer, 2008, May 1, 112(9):2011-2020. 16) Narasimhan, M, Rose, R, Ramakrishnan, R, Zell, JA, Rathinavelu, A. Identification of HDM2 as a regulator of VEGF expression in cancer cells. Life Sci. 2008 Jun 18;82(25-26):1231-41. 17) Ou, S-HI, Zell, JA Prognostic significance of the number of lymph nodes removed at lobectomy in stage IA non-small cell lung cancer (NSCLC). J Thor Oncol, 2008, August, Vol 3(8):880-886. 18) Le, H, Ziogas, A, Lipkin, SM, Zell, JA* Effects of socioeconomic status and treatment disparities in colorectal cancer survival. Cancer Epi Biomarkers & Prev, 2008, August, Vol. 17(8): 1950-1952. 19) Le, H, Rhee, JM, Ziogas, A, Lee, JG, Lipkin, SM, Zell, JA* A population-based, descriptive analysis of malignant intraductal papillary mucinous neoplasms (IPMNs) of the pancreas Cancer Epi Biomarkers & Prev, 2008, October, Vol 17(10): 2737-2741. 20) Zell, JA*, Honda, J, Ziogas, A, Anton-Culver, H. Survival after Colorectal Cancer Diagnosis is Associated with Colorectal Cancer Family History Cancer Epi Biomarkers & Prevention, 2008, November 17(11): 3134-3140. 21) Le, H, Ziogas, A, Taylor, TH, Lipkin, SM, Zell, JA* Survival of distinct Asian groups among colorectal cancer cases in California Cancer, 2009, January 115 (2):259-270. 22) Ou, S-HI, Ziogas, A, Zell, JA Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): the importance of smoking history, socioeconomic and marital statuses, and ethnicity J Thor Oncol, 2009, January, 4(1):37-43. 23) Ou, S-HI, Zell, JA The applicability of the proposed IASLC staging revisions to small cell lung cancer (SCLC) with comparison to the current AJCC 6th TNM edition J Thor Oncol, 2009, February, 4(2): In Press. 24) Wray, C, Hinojosa, MW, Ziogas, A, Le, H, Stamos, MJ, and Zell, JA* Tumor subsite location within the colon is prognostic for survival after colon cancer diagnosis Dis Colon Rectum, Accepted December 27, 2008. 25) Zell, JA*, Pelot, D, Chen, W-P, McLaren, CE, Gerner, EW, Meyskens, FL Risk of Cardiovascular Events in a Randomized Placebo-Controlled, Double-Blind Trial of Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas Cancer Prevention Research, 2008, Accepted Dec. 31, 2008. |
|
|
Book Chapters: Zell, JA and Meyskens, FL. Chapter 27: Cancer Prevention, Screening, and Early Detection. In Abeloff, Clinical Oncology, 4th ed. Churchill Livingstone, An Imprint of Elsevier, May 2008. Zell, JA. Arginine and Cancer. In Encyclopedia of Cancer 2nd ed. Springer-Verlag, 2009. ISBN: 978-3-540-36847-2 |
||
| Grants | Protocol UCI 06-8-01 (Contract N01-CN-35160) Feb. 8, 2008-Feb. 7, 2010 NIH/NCI Co-investigator: Funded by NCI as a contract under the larger UC Irvine chemoprevention consortium contract to conduct multiple early phase clinical trials for candidate cancer preventive agents. Phase IIa chemoprevention clinical biomarker trial investigating erlotinib treatment on EGF biomarker effects in aberrant crypt foci in patient with adenoma or resected stage I-III colon cancer. | |
| Protocol UCI 2007-5892 July 17th, 2008-November 1, 2010 NIH/NCRR Principle Investigator: “Phase IIA clinical biomarker trial of aspirin and arginine restriction in colon cancer patients”. ClinicalTrials.gov Identifier: NCT00578721 Trial is supported by Public Health Service research grant M01 RR00827 from the National Center for Research Resources. | ||
| Southwest Oncology Group (SWOG) & The Hope Foundation. Charles Coltman Fellowship Award. July 1st, 2009-June 30, 2011. | ||
|
Professional Societies |
American Board of Internal Medicine (ABIM) American Association for Cancer Research American Society of Hematology American Society of Clinical Oncology Southwest Oncology Group (SWOG) American Society of Preventive Oncology (ASPO) |
|
| Other Experience |
Faculty Member U.S. National Cancer Institute - Middle East Cancer Consortium (MECC), Istanbul, Turkey 2007 |
|
|
Diplomat (Board Certified) American Board of Internal Medicine, Internal Medicine 2004 |
||
|
Diplomat (Board Certified) American Board of Internal Medicine, Medical Oncology 2008 |
||
| Graduate Programs |
Epidemiology |
|
| Research Center | UCI Genetic Epidemiology Research Institute (GERI) | |
| Link to this profile | http://www.faculty.uci.edu/profile.cfm?faculty_id=5483 | |
| Last updated | 01/13/2009 | |